Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.

ABSTRACT:

SUBMITTER: Dooley KE 

PROVIDER: S-EPMC7301745 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature